Pfizer & Wyeth: acquiring to survive, rather than to grow

Abstract

This case focus on the strategy that motivated Pfizer to go, by 2009, through the acquisition of Wyeth. Beyond the strategic reasons, this case will discuss the financial implications of the deal jointly analysing the impact on financial key ratios for Pfizer’s investors. As the historical Pfizer’s portfolio of acquisitions is considerably extended, its investors are left with questions about the realization of the synergies announced as well as the ability to integrate Wyeth’s business in such a tough period.